Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chevron beats estimates on record Q3 production, despite weak crude price

(Sharecast News) - Chevron posted better-than-expected third-quarter results, driven by record production, offsetting weaker oil prices. On a constant currency basis and excluding costs associated with the acquisition of Hess, Chevron earned $1.85 per share, beating forecasts of $1.68 per share.

The oil giant pumped a record 4.1 million barrels a day, a 21% increase compared with the same period last year. Higher production came from the Hess acquisition, the Permian Basin, the Gulf of Mexico and Kazakhstan.

"Third quarter results reflect record production, strong cash generation and sustained superior cash returns to shareholders," said chief executive Mike Wirth.

"The integration of Hess is progressing well, unlocking synergies across our operations and positioning Chevron as a premier global energy company."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Aeorema Communications shares jump on guidance upgrade
(Sharecast News) - Shares in Aeorema Communications jumped on Tuesday after the AIM-listed strategic comms firm hiked its profit guidance for the full year following a strong start to the second half.
Citi lifts price target on Vodafone, maintains 'neutral' rating
(Sharecast News) - Citi lifted its price target on Vodafone on Tuesday to 127p from 110p as it said scope for positive news was stopping it from taking a more cautious stance.
MJ Gleeson swings to full-year loss, cuts dividend
(Sharecast News) - MJ Gleeson said on Tuesday that it swung to a full-year pre-tax loss in a 'subdued' market, as it took a hit from exceptional costs of £13.6m.
Deutsche Bank upgrades Astrazeneca to 'hold'
(Sharecast News) - Deutsche Bank upgraded Astrazeneca from 'sell' to 'hold' on Tuesday and nudged its price target up from 11,500p to 11,700p, saying the risk‑reward scenario had shifted following last week's negative SERENA-4 readout and a period of underperformance against European large‑cap peers.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.